|
시장보고서
상품코드
1966117
담관암 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Bile Duct Cancer Drug Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
담관암 치료제 시장 규모는 2025년 2억 6,917만 달러에서 2034년에는 5억 3,094만 달러에 달할 것으로 예측되고 있으며, 2026-2034년에 CAGR 7.84%로 성장할 전망입니다.
담관암(담관세포암) 치료제 시장은 질환의 희소성과 진단 시기가 늦어 기존에는 규모가 작았습니다. 그러나 표적치료제와 면역항암제의 등장으로 다시 주목받고 있습니다. 기존에는 화학요법이 오랜 기간 표준치료였으나, 유전체 분석으로 치료 가능한 돌연변이(IDH1, FGFR2 융합 등)가 밝혀지면서 표적 억제제 개발 및 틈새 적응증 승인이 진행되었습니다. 종양학 센터의 분자 검사 증가로 치료 가능한 아형의 진단율이 높아지면서 대상 환자군과 투자자들의 관심이 확대되고 있습니다.
주요 성장 요인은 정밀 종양학의 발전, 표적 약물의 규제 승인, 분자진단에 대한 접근성 확대 등입니다. 종양학 네트워크와 환자 지원 단체의 지원으로 전 세계에서 임상시험 활동 증가. 이로 인해 적응증 확대와 특정 집단에 대한 적응증 외 사용이 가속화되었습니다. 동반진단과 바이오마커 기반의 환자 등록을 통해 절대적인 환자 수가 적은 상황에서도 개발 효율성이 향상되고, 시장은 고부가가치 전문 치료로 전환되고 있습니다.
앞으로의 전망은 조심스럽지만 낙관적입니다. 치료 가능한 돌연변이의 지속적인 발굴과 면역요법과의 병용 전략으로 치료 선택의 폭을 넓히고 생존율을 향상시킬 수 있을 것으로 기대됩니다. 시장 확대는 게놈 검사의 보급, 고가의 표적치료제에 대한 상환 정책, 지속적인 효과를 입증하는 후기 임상시험의 성공 여부에 달려있습니다. 질환의 희소성, 환자 1인당 고가의 가격, 표적치료제 간의 경쟁, 도입 촉진을 위한 동반진단과 실제 데이터에 대한 중요성이 부각될 것으로 예측됩니다.
목차
제1장 서론
제2장 개요
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 담관암 치료제 시장 : 표적치료별
제5장 세계의 담관암 치료제 시장 : 용도별
제6장 세계의 담관암 치료제 시장 : 적응 질환별
제7장 세계의 담관암 치료제 시장 : 유통 채널별
제8장 세계의 담관암 치료제 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSA 26.03.24The Bile Duct Cancer Drug Market size is expected to reach USD 530.94 Million in 2034 from USD 269.17 Million (2025) growing at a CAGR of 7.84% during 2026-2034.
The bile duct (cholangiocarcinoma) drug market has historically been small due to disease rarity and late-stage diagnosis, but it has seen renewed interest as targeted therapies and immuno-oncology agents emerge. Traditional chemotherapy remained the standard for years, but genomic profiling revealed actionable mutations (IDH1, FGFR2 fusions, etc.), prompting development of targeted inhibitors and niche approvals. Increased molecular testing at oncology centers has elevated diagnosis of targetable subtypes, expanding addressable patient populations and investor interest.
Primary growth drivers are advances in precision oncology, regulatory approvals of targeted agents, and expanding access to molecular diagnostics. Clinical trial activity has increased globally, supported by oncology networks and patient advocacy; this has accelerated label expansions and off-label use in select populations. Companion diagnostics and biomarker-driven enrollment have made development more efficient despite small absolute patient numbers, shifting the market toward high-value, specialized therapies.
Future prospects are cautiously optimistic: continued identification of actionable mutations and combination strategies with immunotherapies could broaden therapeutic options and improve survival. Market expansion depends on wider availability of genomic testing, reimbursement policies for expensive targeted agents, and successful late-stage trials demonstrating durable benefit. Given the orphan nature of the disease, expect high per-patient pricing, rising competition among targeted therapies, and an emphasis on companion diagnostics and real-world evidence to support uptake.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Targeted Therapy
- Pemigatinib
- Infigratinib (Phase 3)
- Ivosidenib (Phase 3)
- Immunotherapy (Pembrolizumab (Phase 3))
- Others
By Application
- Hospitals
- Clinics
- Others
By Disease Indication
- Intrahepatic Bile Duct Cancer
- Extrahepatic Bile Duct Cancer
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
COMPANIES PROFILED
- Johnson Johnson Private Limited, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GlaxoSmithKline plc, AbbVie Inc, Novartis AG, Fresenius Kabi AG, Eli Lilly and Company, F HoffmannLa Roche Ltd, Intercept Pharmaceuticals, Kyowa Kirin Co Ltd, Delcath Systems Inc
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL BILE DUCT CANCER DRUG MARKET: BY TARGETED THERAPY 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Targeted Therapy
- 4.2. Pemigatinib Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Infigratinib (Phase 3) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Ivosidenib (Phase 3) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.5. Immunotherapy (Pembrolizumab (Phase 3)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL BILE DUCT CANCER DRUG MARKET: BY APPLICATION 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Application
- 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL BILE DUCT CANCER DRUG MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Disease Indication
- 6.2. Intrahepatic Bile Duct Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Extrahepatic Bile Duct Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL BILE DUCT CANCER DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast Distribution Channel
- 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL BILE DUCT CANCER DRUG MARKET: BY REGION 2022-2034(USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Targeted Therapy
- 8.2.2 By Application
- 8.2.3 By Disease Indication
- 8.2.4 By Distribution Channel
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Targeted Therapy
- 8.3.2 By Application
- 8.3.3 By Disease Indication
- 8.3.4 By Distribution Channel
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Targeted Therapy
- 8.4.2 By Application
- 8.4.3 By Disease Indication
- 8.4.4 By Distribution Channel
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Targeted Therapy
- 8.5.2 By Application
- 8.5.3 By Disease Indication
- 8.5.4 By Distribution Channel
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 South East Asia
- 8.5.10 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Targeted Therapy
- 8.6.2 By Application
- 8.6.3 By Disease Indication
- 8.6.4 By Distribution Channel
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL BILE DUCT CANCER DRUG INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 Johnson & Johnson Private Limited
- 10.2.2 Mylan N.V
- 10.2.3 Teva Pharmaceutical Industries Ltd
- 10.2.4 Sanofi
- 10.2.5 Pfizer Inc
- 10.2.6 GlaxoSmithKline Plc
- 10.2.7 AbbVie Inc
- 10.2.8 Novartis AG
- 10.2.9 Fresenius Kabi AG
- 10.2.10 Eli Lilly And Company
- 10.2.11 F. Hoffmann-La Roche Ltd
- 10.2.12 Intercept Pharmaceuticals
- 10.2.13 Kyowa Kirin Co. Ltd
- 10.2.14 Delcath Systems Inc
